Free Trial

Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

Thermo Fisher Scientific logo
$513.77 -6.13 (-1.18%)
Closing price 03/25/2025 03:58 PM Eastern
Extended Trading
$515.00 +1.23 (+0.24%)
As of 03/25/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
18

Based on 22 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, and 18 have given a buy rating for TMO.

Consensus Price Target

$653.23
27.14% Upside
According to the 22 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $653.23. The highest price target for TMO is $715.00, while the lowest price target for TMO is $570.00. The average price target represents a forecasted upside of 27.14% from the current price of $513.77.
Get the Latest News and Ratings for TMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors.

Sign Up

TMO Analyst Ratings Over Time

TypeCurrent Forecast
3/26/24 to 3/26/25
1 Month Ago
2/25/24 to 2/24/25
3 Months Ago
12/27/23 to 12/26/24
1 Year Ago
3/27/23 to 3/26/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
18 Buy rating(s)
18 Buy rating(s)
16 Buy rating(s)
10 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$653.23$656.86$650.05$599.00
Forecasted Upside27.14% Upside22.65% Upside23.31% Upside5.23% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Remove Ads

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Thermo Fisher Scientific Stock vs. The Competition

TypeThermo Fisher ScientificMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside27.14% Upside29,987.76% Upside17.45% Upside
News Sentiment Rating
Positive News

See Recent TMO News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/4/2025Citigroup
3 of 5 stars
Patrick Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$650.00 ➝ $570.00+10.42%
2/3/2025Scotiabank
5 of 5 stars
S. Nam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Perform ➝ Sector Perform$605.00 ➝ $650.00+9.44%
2/3/2025Raymond James
4 of 5 stars
Andrew Cooper
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$650.00 ➝ $667.00+11.46%
1/31/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Conor McNamara
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$693.00+30.13%
1/31/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Leonard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$700.00 ➝ $715.00+19.20%
1/31/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$660.00 ➝ $680.00+12.98%
1/31/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tejas Savant
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$647.00 ➝ $678.00+12.52%
1/10/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Burstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$630.00+15.60%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$675.00 ➝ $660.00+26.05%
10/24/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$680.00 ➝ $665.00+17.72%
10/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$630.00 ➝ $620.00+9.38%
10/24/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$632.00 ➝ $622.00+7.89%
10/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$620.00 ➝ $610.00+6.63%
10/22/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$656.00 ➝ $686.00+16.92%
10/22/2024Bernstein Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$565.00 ➝ $625.00+6.30%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$680.00+13.74%
10/1/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$680.00+9.93%
9/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$650.00 ➝ $670.00+9.13%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Buy$600.00 ➝ $650.00+14.44%
4/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$660.00 ➝ $670.00+17.13%
4/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$600.00 ➝ $610.00+6.54%
4/10/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$550.00 ➝ $640.00+10.94%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$575.00+15.58%
10/26/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Sector Weight
7/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$620.00+17.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:03 AM ET.


Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 23, 2025. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

  • The stock is currently priced at $518.04, which may present a buying opportunity for investors looking for growth in the life sciences sector.
  • Thermo Fisher Scientific Inc. reported earnings per share (EPS) of $6.10 for the last quarter, exceeding analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has a solid market capitalization of $195.44 billion, reflecting its stability and position as a leader in the life sciences and analytical instruments market.
  • Recent analyst ratings show a consensus of "Moderate Buy" with a price target of $653.23, suggesting that analysts expect the stock to appreciate in value.
  • Thermo Fisher Scientific Inc. has increased its quarterly dividend to $0.43 per share, demonstrating a commitment to returning value to shareholders and a healthy payout ratio of 10.41%.

Thermo Fisher Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

  • The stock has experienced a slight decline of 0.1%, which may indicate short-term volatility and uncertainty in the market.
  • Insider selling has been noted, with executives selling a total of 23,900 shares valued at over $13 million, which could signal a lack of confidence in the stock's short-term performance.
  • The company has a relatively high P/E ratio of 31.34, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
  • Despite strong earnings, the price-to-earnings-growth (PEG) ratio of 2.99 indicates that the stock may not be growing fast enough to justify its current valuation, which could deter value-focused investors.
  • With only 0.34% of the stock owned by insiders, there may be a lack of alignment between management and shareholder interests, which can be a red flag for potential investors.

TMO Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $653.23, with a high forecast of $715.00 and a low forecast of $570.00.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last twelve months. There are currently 4 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMO shares.

According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 27.14% based on their 12-month stock forecasts.

Over the previous 90 days, Thermo Fisher Scientific's stock had 1 upgrade by analysts.

Thermo Fisher Scientific has been rated by research analysts at Citigroup, Morgan Stanley, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Thermo Fisher Scientific less than other "medical" companies. The consensus rating score for Thermo Fisher Scientific is 2.82 while the average consensus rating score for "medical" companies is 2.82. Learn more on how TMO compares to other companies.


This page (NYSE:TMO) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners